Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14327665 | 0.79 | OPRM1 (0.31) | OPRM1OPRK1 | |
| SCHEMBL880389 | 0.78 | OPRM1 (0.31) | OPRM1OPRD1OPRK1OPRL1OGFRL1 | |
| SCHEMBL10285474 | 0.77 | ALDH1A1 (0.31) | — | |
| SCHEMBL13243090 | 0.77 | ALDH1A1 (0.38) | — | |
| SCHEMBL16731191 | 0.76 | — | — | |
| SCHEMBL880511 | 0.75 | ALDH1A1 (0.30) | — | |
| SCHEMBL10285470 | 0.74 | ACHE (0.33) | OPRM1OPRD1OPRK1OPRL1OGFRL1 | |
| SCHEMBL880527 | 0.74 | ACHE (0.33) | OPRM1OPRD1OPRK1OPRL1OGFRL1 | |
| SCHEMBL12345491 | 0.70 | — | — | |
| SCHEMBL12652960 | 0.69 | PHGDH (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216726-A1 | Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof | PURDUE PHARMA L.P. (US) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216726-A1 | Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof | P2RX4, P2RX5, P2RX3 | OPRM1 25/4885OPRD1 29/4885OPRK1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.